umbilical cord blood + human placental-derived stem cells

This drug is a **combination cell therapy** composed of stem cells derived from **umbilical cord blood** and **human placenta**. Both sources are rich in progenitor and stem cell populations—including hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and endothelial progenitor cells—that possess angiogenic, neuroregenerative, immunomodulatory, and tissue-repair properties[1][2][3][5]. The mechanism of action involves **regeneration, modulation of immune responses, reduction of inflammation, and facilitation of tissue repair**. Umbilical cord blood is primarily a source of naive HSCs and multipotent progenitor cells, while placental tissues can provide additional MSCs and other niche cell types that enhance therapeutic outcomes[2][3][5]. This combination is being investigated for numerous indications, most notably **hematological disorders** (including transplantation), **COVID-19 and other lung diseases**, **neurological conditions** (such as cerebral palsy and stroke), **orthopedic disorders**, and **autoimmune diseases**[1][2][3]. The drug remains investigational, mainly studied in clinical trials aiming to expand the potential of perinatal cell therapy for regenerative medicine and immune modulation[1][3].

Other names

cord blood + placenta-derived stem cellsperinatal stem cell combination